Associated tags: NSCLC, Head, VISTA, Neck, Immunoglobulin G, Immunosuppression, Lung, Tumor microenvironment, Immunotherapy, Cancer, Kineta, Patient, Pharmaceutical industry, Vaccine
Locations: SEATTLE, WA, US, NJ, USA
Combination,
CPI,
Immunosuppression,
Patient,
Tumor microenvironment,
Immunoglobulin G,
Merck,
Cancer,
Pembrolizumab,
Lung cancer,
AACR,
DLT,
Clinical trial,
Merck & Co.,
Kineta,
NK,
VISTA,
Pharmaceutical industry SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.
Key Points:
- KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
- KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
- Patients currently enrolled in the trial will be permitted to continue to participate.
- KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Research,
Combination,
CPI,
AML,
Caregiver,
Bone marrow,
Insurance,
Patient,
Merck,
Acute myeloid leukemia,
Cancer,
Public expenditure,
Pembrolizumab,
Lung cancer,
Trial of the century,
Cytokine release syndrome,
AACR,
Chemokine,
Clinical trial,
Annual report,
Safety,
Workforce,
Infrared spectroscopy correlation table,
NK,
VISTA,
Pharmaceutical industry SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.
Key Points:
- In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
- We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
- Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
- Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.
Combination,
CPI,
Immunosuppression,
Patient,
Tumor microenvironment,
Merck,
Cancer,
Pembrolizumab,
Lung cancer,
DLT,
Merck & Co.,
Kineta,
NK,
Pharmaceutical industry SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
Key Points:
- KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
- KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
- We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
- KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Retrieved on:
Thursday, February 29, 2024
Following this review, Kineta is implementing a significant corporate restructuring to substantially reduce expenses and preserve cash.
Key Points:
- Following this review, Kineta is implementing a significant corporate restructuring to substantially reduce expenses and preserve cash.
- The company will conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value including potential sale of assets of the company, a sale of the company, licensing of assets, a merger, liquidation or other strategic action.
- There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.
- Kineta is reducing its workforce by approximately 64%, which will result in the elimination of seven positions.
Retrieved on:
Thursday, February 22, 2024
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.
Key Points:
- SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.
- Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.
- The abstract will be published as a freely available supplement in an AACR journal on the first day of the symposium.
- The poster will also be made available on the Kineta website following the presentation at the conference.
Retrieved on:
Wednesday, February 14, 2024
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:
Key Points:
- SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:
Location: The New York Marriott Marquis, Uris room
The Company will be available for one-on-one meetings during the conferences.
- Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Retrieved on:
Wednesday, February 7, 2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024.
Key Points:
- SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024.
- Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta and Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present an overview of recent clinical results of KVA12123, the company’s VISTA blocking immunotherapy in development for patients with advanced solid tumors.
- The webcast presentation replay will be available for viewing on the Events & Presentations section of the Company's website.
Retrieved on:
Wednesday, January 17, 2024
CXCL10,
NK,
Tumor microenvironment,
CCL2,
Chemokine,
Patient,
Radiation,
Cytokine,
Merck & Co.,
CCL3,
Cancer,
Immunotherapy,
Cytokine release syndrome,
CRS,
Blood,
Safety,
CCL4,
VISTA,
Immunosuppression,
Biomarker,
Pembrolizumab,
Merck,
Clinical trial,
TME,
Infrared spectroscopy correlation table,
DLT,
Trial of the century,
IL-6,
Pharmaceutical industry SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking immunotherapy, cleared the first four monotherapy dose levels and the first cohort in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level. Additionally, KVA12123 demonstrates robust and dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, demonstrating on target effects of blocking VISTA.
Key Points:
- Additionally, KVA12123 demonstrates robust and dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, demonstrating on target effects of blocking VISTA.
- “We are encouraged with the efficacy-related biomarker data that demonstrate on-target activity of KVA12123 in our Phase 1/2 clinical trial.
- To guide the recommended Phase 2 dose (RP2D) decision, Kineta developed a proprietary assay to evaluate VISTA RO on immune cells from patients in the clinical trial.
- The drug has been very well tolerated in patients,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
Retrieved on:
Thursday, January 4, 2024
SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.
Key Points:
- SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.
- “We look forward to participating in the LifeSci Corporate Access Event and to hosting in-person meetings with investors, strategic partners, analysts and other stakeholders”, said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta.
- “2024 has the potential to be a substantial growth year as we continue to make significant progress on the clinical development of KVA12123, our novel VISTA immunotherapy.”
During the event, the Kineta management team will host one-on-one meetings on January 8th and 9th, 2024 and will be available to present a corporate overview and provide an update on the VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors.
Retrieved on:
Wednesday, December 13, 2023
Immunotherapy,
Tumor microenvironment,
Arm,
Cancer,
Kineta,
Pembrolizumab,
VISTA,
Patient,
Safety,
Immunoglobulin G,
Vaccine SEATTLE, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the peer-reviewed publication in Frontiers in Immunology of preclinical data highlighting the potential of KVA12123 as a new immunotherapy against poorly immunogenic tumors. The publication titled “A Highly Potent Anti-VISTA Antibody KVA12123 - A New Immune Checkpoint Inhibitor and a Promising Therapy Against Poorly Immunogenic Tumors”, reports on the development of KVA12123.
Key Points:
- The publication titled “ A Highly Potent Anti-VISTA Antibody KVA12123 - A New Immune Checkpoint Inhibitor and a Promising Therapy Against Poorly Immunogenic Tumors ”, reports on the development of KVA12123.
- “This scientific article summarizes the extensive characterization and selection of our clinical candidate KVA12123 that targets VISTA, a strong driver of immune suppression in the tumor microenvironment,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
- “The publication highlights the differentiating potency and safety characteristics of KVA12123 that guided its advancement into clinical development.
- Additional clinical efficacy data in the monotherapy arm and initial combination data with pembrolizumab are anticipated in Q2 2024.
